Oncology

Trastuzumab deruxtecan combined with pertuzumab significantly delayed disease progression compared to standard care in patients with HER2-positive advanced breast cancer, according to initial findings from the DESTINY-Breast09 Phase III trial.

Breast cancer survivors may face a lower risk of Alzheimer’s disease than their cancer-free peers, according to a large retrospective cohort study examining long-term cognitive outcomes following treatment.

Pro-inflammatory diets may increase the risk of death in patients with Stage III colon cancer, according to a new analysis of dietary patterns in a large cohort of U.S. patients.

A randomized controlled trial has found that Bojungikgi-tang (BJT), a traditional East Asian herbal medicine, significantly improved symptoms of anorexia and atopic dermatitis (AD) while altering the gut microbiome in affected patients.

Switching to camizestrant upon detection of an ESR1 mutation, before clinical disease progression, may extend progression-free survival (PFS) for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to results from the Phase III SERENA-6 trial.

As cancer therapies evolve and autoimmune diseases become more prevalent, the intersection of oncology and rheumatology, onco-rheumatology, is emerging as a critical field demanding transdisciplinary care.

Efforts to optimize treatment for Stage II testicular seminoma are intensifying, as new approaches aim to reduce long-term toxicity while preserving the high cure rates associated with standard therapies.

In a large retrospective study, percutaneous balloon dilation was found to have a statistically significant advantage over open reconstructive surgery for treating high-grade benign biliary strictures, especially those classified as Bismuth-Strasberg type E4 and E5, which are known for technical complexity and recurrence risk.